---
layout: default
title: Acetazolamide
description: "Acetazolamide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 12
evidence_level: L2
indication_count: 10
---

# Acetazolamide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Acetazolamideï¼šå¾é’å…‰çœ¼åˆ©å°¿åˆ°å¿ƒè‚Œç—…è®Šæ¢ç´¢

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Acetazolamide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Acetazolamide åŸæœ¬ç”¨æ–¼é’å…‰çœ¼åŠåˆ©å°¿ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¿ƒè‚Œç—…è®Š (cardiomyopathy)** åŠ**è‚¥åšæ€§å¿ƒè‚Œç—…è®Š (hypertrophic cardiomyopathy)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **3 å€‹è‡¨åºŠè©¦é©—**å’Œ **11 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é’å…‰çœ¼ã€ç™²ç™‡ã€å……è¡€æ€§å¿ƒè¡°ç«­æ°´è…« |
| é æ¸¬æ–°é©æ‡‰ç—‡ | exercise-induced malignant hyperthermiaã€hypertrophic cardiomyopathyã€congenital myopathy with excess of thin filamentsã€hypertrophic cardiomyopathy due to intensive athletic trainingã€distal myopathy, Tateyama typeã€cirrhotic cardiomyopathyã€å¿ƒè‚Œç—…è®Šã€intestinal obstructionã€glycogen storage disease due to acid maltase deficiency, late-onsetã€myopathic intestinal pseudoobstruction |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.83% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 22 å¼µï¼ˆéƒ¨åˆ†å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. exercise-induced malignant hyperthermia</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.95%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Acetazolamide æ˜¯ç¢³é…¸é…é…¶æŠ‘åˆ¶åŠ‘ï¼Œå‚³çµ±ä¸Šç”¨æ–¼é’å…‰çœ¼å’Œåˆ©å°¿ã€‚è¿‘å¹´ç ”ç©¶ç™¼ç¾å…¶åœ¨æ€¥æ€§å¤±ä»£å„Ÿæ€§å¿ƒè¡°ç«­ä¸­çš„æ‡‰ç”¨åƒ¹å€¼é¡¯è‘—æå‡ã€‚

ADVOR è©¦é©— (2022) é¡¯ç¤ºï¼Œacetazolamide åŠ ä¸Š loop diuretics å¯é¡¯è‘—æ”¹å–„æ€¥æ€§å¿ƒè¡°ç«­æ‚£è€…çš„å»é¬±è¡€æ•ˆæœã€‚å…¶æ©Ÿè½‰åŒ…æ‹¬ï¼š
1. æŠ‘åˆ¶è¿‘ç«¯è…å°ç®¡ç¢³é…¸é…é…¶ï¼Œå¢åŠ éˆ‰é›¢å­æ’æ³„
2. å…‹æœåˆ©å°¿åŠ‘æŠµæŠ—
3. èª¿ç¯€é›»è§£è³ªå¹³è¡¡ï¼ˆç‰¹åˆ¥æ˜¯æ°¯é›¢å­ï¼‰

å°æ–¼å¿ƒè‚Œç—…è®Šæ‚£è€…ï¼Œå¸¸ä¼´éš¨å¿ƒè¡°ç«­ç—‡ç‹€ï¼Œacetazolamide ä½œç‚ºè¼”åŠ©åˆ©å°¿åŠ‘çš„è§’è‰²å·²ç²è‡¨åºŠé©—è­‰ã€‚æ­¤å¤–ï¼Œ2018 å¹´æ—¥æœ¬å€‹æ¡ˆå ±å‘Šé¡¯ç¤ºï¼Œacetazolamide å¯ç”¨æ–¼æ²»ç™‚è‚¥åšæ€§å¿ƒè‚Œç—…è®Šåˆä½µä½æ°¯è¡€ç—‡æ‚£è€…ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT05802849](https://clinicaltrials.gov/study/NCT05802849) | Phase 4 | RECRUITING | 400 | è©•ä¼° acetazolamide å£æœåœ¨å¤±ä»£å„Ÿæ€§å¿ƒè¡°ç«­ï¼ˆåŒ…æ‹¬å¿ƒè‚Œç—…è®Šï¼‰ä¸­çš„ç™‚æ•ˆ |
| [NCT06166654](https://clinicaltrials.gov/study/NCT06166654) | Phase 4 | RECRUITING | 939 | æ¯”è¼ƒ loop diuretics åˆä½µ Metolazone æˆ– Acetazolamide åœ¨æ€¥æ€§å¿ƒè¡°ç«­å®¹é‡éè² è·çš„æ•ˆæœ |
| [NCT06092437](https://clinicaltrials.gov/study/NCT06092437) | N/A | RECRUITING | 466 | TAILOR-AHFï¼šå°¿éˆ‰å°å‘çš„åˆ©å°¿åŠ‘æ¼”ç®—æ³•ç ”ç©¶ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [41696050](https://pubmed.ncbi.nlm.nih.gov/41696050/) | 2026 | Case Report | Int J Heart Fail | åˆ©å°¿åŠ‘æŠµæŠ—æ€§æ™šæœŸå¿ƒè¡°ç«­ä½¿ç”¨ acetazolamide æˆåŠŸä½œç‚ºç§»æ¤å‰æ©‹æ¥æ²»ç™‚ |
| [38806171](https://pubmed.ncbi.nlm.nih.gov/38806171/) | 2025 | Review | ESC heart failure | 2024 å¿ƒè¡°ç«­æ›´æ–°ï¼šè‚¯å®š acetazolamide åŠ  loop diuretics çš„è¯åˆç™‚æ³• |
| [37169875](https://pubmed.ncbi.nlm.nih.gov/37169875/) | 2023 | Journal Article | Eur Heart J Cardiovasc Pharmacother | 2022 å¹´å¿ƒè¡€ç®¡è—¥ç†é€²å±•å›é¡§ï¼Œacetazolamide è¯åˆ loop diuretics è¢«ç´å…¥æ¨™æº–æ²»ç™‚ |
| [30279861](https://pubmed.ncbi.nlm.nih.gov/30279861/) | 2018 | Case Report | J Cardiol Cases | è‚¥åšæ€§å¿ƒè‚Œç—…è®Šåˆä½µä½æ°¯è¡€ç—‡ï¼Œä½¿ç”¨ acetazolamide æˆåŠŸçŸ¯æ­£é›»è§£è³ª |
| [742352](https://pubmed.ncbi.nlm.nih.gov/742352/) | 1978 | Journal Article | Acta Neurol Scand | ä½é‰€é€±æœŸæ€§éº»ç—ºèˆ‡å¿ƒè‚Œç—…è®Šä¹‹é—œè¯ç ”ç©¶ |
| [7324871](https://pubmed.ncbi.nlm.nih.gov/7324871/) | 1981 | Case Report | Acta Neurol Scand | å®¶æ—æ€§ä½é‰€é€±æœŸæ€§éº»ç—ºä¸­ç™¼ç¾å¿ƒè‚Œç–¾ç—…è­‰æ“š |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hypertrophic cardiomyopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.93%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. congenital myopathy with excess of thin filaments</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hypertrophic cardiomyopathy due to intensive athletic training</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. distal myopathy, Tateyama type</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.88%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. cirrhotic cardiomyopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.88%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cardiomyopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.83%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. intestinal obstruction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.82%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. glycogen storage disease due to acid maltase deficiency, late-onset</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.80%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. unclassified intestinal pseudoobstruction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.79%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.79%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è£½å­—ç¬¬007548è™Ÿ | "äººäºº" ä¹™é†¯å¶æ°®èƒºéŒ  | éŒ åŠ‘ | é’å…‰çœ¼åŠæ°´è…«ã€ç™²ç™‡è¼”åŠ©æ²»ç™‚ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027543è™Ÿ | ä¹™é†¯å¶æ°®èƒº | ç²‰åŠ‘ | ç¢³é…¸é…é…¶æŠ‘åˆ¶è—¥ |
| è¡›ç½²è—¥è£½å­—ç¬¬023932è™Ÿ | "æ–°å–œ" å£“ä½œéŒ  | éŒ åŠ‘ | é’å…‰çœ¼ã€å……è¡€æ€§å¿ƒä¸å…¨ä¹‹æ°´è…« |
| è¡›ç½²è—¥è£½å­—ç¬¬007819è™Ÿ | å®‰è³œä»–æ˜éŒ  | éŒ åŠ‘ | é’å…‰çœ¼åŠæ°´è…«ã€ç™²ç™‡è¼”åŠ©æ²»ç™‚ |

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨

**Major äº¤äº’ä½œç”¨ï¼š**
- Aspirinï¼ˆé«˜åŠ‘é‡ï¼‰ï¼šå¢åŠ  acetazolamide æ¯’æ€§é¢¨éšªï¼Œå¯èƒ½å¼•èµ·ä»£è¬æ€§é…¸ä¸­æ¯’

**Moderate äº¤äº’ä½œç”¨ï¼š**
- é™è¡€ç³–è—¥ç‰©ï¼ˆå„é¡å£æœé™ç³–è—¥ã€èƒ°å³¶ç´ ï¼‰ï¼šå¯èƒ½å½±éŸ¿è¡€ç³–æ§åˆ¶
- Amphotericin Bï¼šå¢åŠ ä½é‰€è¡€ç—‡é¢¨éšª
- é¡å›ºé†‡ï¼ˆBetamethasoneã€Budesonide ç­‰ï¼‰ï¼šå¢åŠ ä½é‰€è¡€ç—‡é¢¨éšª
- Bisacodylï¼šé›»è§£è³ªå¤±è¡¡é¢¨éšª
- Digoxinï¼šä½é‰€å¯èƒ½å¢åŠ æ¯›åœ°é»ƒæ¯’æ€§
- Lithiumï¼šå¯èƒ½å¢åŠ é‹°æ¯’æ€§
- Metforminï¼šå¯èƒ½å¢åŠ ä¹³é…¸é…¸ä¸­æ¯’é¢¨éšª
- Carbamazepineã€Phenytoinï¼šå¯èƒ½å½±éŸ¿æŠ—ç™²ç™‡è—¥è¡€ä¸­æ¿ƒåº¦
- Topiramateï¼šå¢åŠ ä»£è¬æ€§é…¸ä¸­æ¯’å’Œè…çµçŸ³é¢¨éšª

### ç¦å¿Œç—‡
- ç£ºèƒºé¡è—¥ç‰©éæ•
- åš´é‡è‚åŠŸèƒ½ä¸å…¨
- ä½éˆ‰è¡€ç—‡æˆ–ä½é‰€è¡€ç—‡
- ä»£è¬æ€§é…¸ä¸­æ¯’
- è‰¾è¿ªæ£®æ°ç—‡

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Acidosis, Respiratory** ğŸŸ¡ Moderate
- Carbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels.  Respiratory acidosis may be precipitated or increased in these patients.  Therapy with carbonic anhydrase inhibitors should be administered cautiou...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- The major route of elimination of carbonic anhydrase inhibitors is through the kidney.  These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment...

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- Elevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with ...

**Gout** ğŸŸ¡ Moderate
- Uric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated.  Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout.  Elevated serum uric acid levels ret...

**Acidosis** ğŸŸ¡ Moderate
- Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors.  Therapy with carbonic anhydrase inhibitors should be administered...

*å¦æœ‰ 7 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Acetazolamide åœ¨æ€¥æ€§å¤±ä»£å„Ÿæ€§å¿ƒè¡°ç«­çš„è¼”åŠ©åˆ©å°¿è§’è‰²å·²æœ‰é«˜å“è³ª RCT è­‰æ“šæ”¯æŒï¼ˆADVOR è©¦é©—ï¼‰ï¼Œä¸”ç›®å‰æœ‰å¤šå€‹ç¬¬å››æœŸè‡¨åºŠè©¦é©—æ­£åœ¨é€²è¡Œä¸­ã€‚å°æ–¼å¿ƒè‚Œç—…è®Šåˆä½µå¿ƒè¡°ç«­çš„æ‚£è€…ï¼Œacetazolamide å¯ä½œç‚ºå…‹æœåˆ©å°¿åŠ‘æŠµæŠ—çš„æœ‰æ•ˆé¸æ“‡ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å¯†åˆ‡ç›£æ¸¬é›»è§£è³ªï¼ˆç‰¹åˆ¥æ˜¯é‰€ã€éˆ‰ã€æ°¯ã€ç¢³é…¸æ°«æ ¹ï¼‰
- é¿å…èˆ‡é«˜åŠ‘é‡ aspirin ä½µç”¨
- ç›£æ¸¬è…åŠŸèƒ½åŠé…¸é¹¼å¹³è¡¡
- è©•ä¼°æ˜¯å¦æœ‰ç£ºèƒºé¡éæ•å²


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Omalizumab]({{ "/drugs/omalizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Regorafenib]({{ "/drugs/regorafenib/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Isosorbide Dinitrate]({{ "/drugs/isosorbide_dinitrate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Acetazolamideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/acetazolamide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_acetazolamide,
  title = {Acetazolamideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/acetazolamide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-21 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
